Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole

scientific article published on December 1, 2003

Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1046/J.1365-2125.2003.01999.X
P953full work available at URLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.2003.01999.x
https://europepmc.org/articles/PMC1884311
https://europepmc.org/articles/PMC1884311?pdf=render
https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2125.2003.01999.x
https://doi.org/10.1046/j.1365-2125.2003.01999.x
https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2125.2003.01999.x
P932PMC publication ID1884311
P698PubMed publication ID14616414
P5875ResearchGate publication ID9010797

P2093author name stringDiane Kleinermans
Don Nichols
Lynn Purkins
Nolan Wood
P2860cites workDrug interactions with fluconazoleQ68764002
Comparative effects of H2-receptor antagonists on drug interaction in ratsQ69890035
Current and emerging azole antifungal agentsQ24550733
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.Q28379300
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonistsQ33860341
Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safetyQ35825582
The clinical importance of drug interactions with antiulcer therapyQ37998709
Review of fluconazole: a new triazole antifungal agentQ38308672
The search for new triazole antifungal agentsQ40884177
Characterization of cimetidine, ranitidine, and related structures' interaction with cytochrome P-450Q42241875
Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatusQ42538222
Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion columnQ47310345
Voriconazole: A second-generation triazoleQ47865467
P407language of work or nameEnglishQ1860
P921main subjectpharmacologyQ128406
P304page(s)51-55
P577publication date2003-12-01
P1433published inBritish Journal of Clinical PharmacologyQ176044
P1476titleHistamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole
Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole
P478volume56 Suppl 1

Reverse relations

cites work (P2860)
Q37144774Accelerated metabolism of voriconazole and its partial reversal by cimetidine
Q38015710Azole interactions with multidrug therapy in pediatric oncology
Q34505582Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Q38284468Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.
Q42218014Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
Q36429699Drug interactions during therapy with three major groups of antimicrobial agents
Q33726698Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Q42173355Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis
Q37775009Management of drug and food interactions with azole antifungal agents in transplant recipients
Q37892536Pharmacogenomics of the triazole antifungal agent voriconazole
Q46807629Safety and pharmacokinetics of coadministered voriconazole and anidulafungin
Q37331953The enzymatic basis of drug-drug interactions with systemic triazole antifungals.
Q34034599Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity
Q37964703Triazole antifungal agents in invasive fungal infections: a comparative review